Brink's Offers to Sell Two Businesses to Win UK CMA Approval for NCR Atleos Deal
BCO is trading near its 52-week low of $91.05 (14% above the low).
Summary
Brink's has offered to sell two of its businesses, NoteMachine/TestLink UK, to address competition concerns raised by the UK Competition and Markets Authority regarding its $6.6 billion acquisition of NCR Atleos. The CMA's formal investigation was launched in August, and its September statement flagged concerns that the deal could reduce competition in the operation and maintenance of ATMs. The divestiture is an undertaking in lieu of a Phase 2 investigation referral, and the CMA has accepted the proposed remedy in principle, noting that the businesses have engaged swiftly and constructively, and will conditionally clear the deal if the undertakings satisfy its concerns. The sale does not impact the $200 million in annual run-rate cost synergies expected within three years of closing. Brink's is committed to selecting a suitable buyer and concluding the divestiture process timely, and is engaged with a number of prospective buyers. The CMA is seeking third-party feedback and considering potential buyers for the divested businesses. The acquisition remains on track for a Q1 2027 close, according to prior company statements.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Brink's named the businesses to be divested as NoteMachine/TestLink UK and said the sale does not impact the $200 million in annual run-rate cost synergies expected within three years of closing.
- Divestiture Process
- The divestiture is to avoid a CMA Phase 2 referral.
- The proposed remedy is an "undertaking in lieu" of a Phase 2 investigation referral.
- Brink's is committed to selecting a suitable buyer and concluding the divestiture process timely.
- The sale process is progressing, and Brink's is engaged with a number of prospective buyers.
- Financial Impact — The potential sale was contemplated in Brink's previously disclosed financial metrics.
All 6 details
- The divestiture is to avoid a CMA Phase 2 referral.
- The proposed remedy is an "undertaking in lieu" of a Phase 2 investigation referral.
- Brink's is committed to selecting a suitable buyer and concluding the divestiture process timely.
- The sale process is progressing, and Brink's is engaged with a number of prospective buyers.
- The potential sale was contemplated in Brink’s previously disclosed financial metrics.
- NCR Atleos Corporation trades on the NYSE under the ticker symbol NATL.
- Divestiture Process
At the time of this announcement, BCO was trading at $103.51 on NYSE in the Trade & Services sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $91.05 to $136.37. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.